With the overuse of electronics, eye patients are increasing
worldwide.
At the same time, the research and development of ophthalmic therapeutic drugs has also begun to attract more and more pharmaceutical companies from all over the world
.
It is reported that at present, the domestic ophthalmic treatment market has become a key area
of the strategic layout of many pharmaceutical companies with a stable growth trend.
Since the beginning of this year, many pharmaceutical companies in this field have also begun to make new moves
.
cooperate
Recently, Vision Biotech and Everads Therapy jointly announced that they will cooperate to develop innovative, safer, more effective and longer-lasting therapies for the treatment of retinal diseases
.
Suprachoroidal injection is a promising drug delivery technique
for targeting fundus diseases.
The suprachoridal space (SCS) refers to the potential space between the choroid and the sclera, and injection in SCS can accurately deliver therapeutic drugs to the site of onset (choroid and retina), and play a targeted therapeutic role in various fundus diseases, so it has attracted great attention
in the field of ophthalmic treatment.
It is reported that the two parties aim to safely and accurately deliver the highly active small molecule innovative therapeutic drugs designed by Everads to the suprachoroidal space of patients through Everads
' unique choroidal injection device and professional technology.
Aiming at scientifically validated retinal disease targets, we will design highly drug-active small molecules
that are more suitable for suprachoroidal injection.
On January 6, Aier Ophthalmology signed a strategic cooperation agreement with Central South University to further strengthen cooperation in talent training, scientific research, platform co-construction, etc.
, give full play to the advantages of science and technology and talents of Central South University, Aier ophthalmology industry and globalization, and jointly build a technology engine and talent training highland
for the coordinated development of Central South University and Aier Ophthalmology.
In fact, as early as 2013, Central South University and Aier Ophthalmology jointly established the Aier Ophthalmology College of
Central South University.
After 10 years of development, the two sides have jointly cultivated more than 300 masters and doctoral ophthalmology talents for the society, undertaken more than 10 national scientific research projects, and published more than 200 SCI journal papers.
.
.
acquisition
On January 9, Puri Eye announced that Dongguan Guangming Eye Hospital recently obtained the business license and "Registration Notice" issued by the Dongguan Market Supervision Administration, and the acquisition of 35% of the equity of Dongguan Guangming Eye Hospital by Chuangfa Enterprise has completed the registration procedures
for industrial and commercial changes.
After the completion of this equity transfer, the company will hold a total of 80% of the equity of Dongguan Guangming Eye Hospital through Chuangfa Enterprise, and Dongguan Guangming Eye Hospital will be included in the scope of
the company's consolidated financial statements.
On January 3, Aier Eye announced that the company plans to invest 470 million yuan to acquire 14 hospitals
including Shaoxing Aier and Zhoushan Aier.
The 14 hospitals acquired have a total revenue of RMB320 million in 2021, with an overall valuation of approximately RMB720 million
.
Most of the hospitals to be acquired are mainly grassroots hospitals, which shows that Aier Eye Department is sinking to the grassroots level
.
It is expected that this acquisition will help improve the regional market layout of Aier Ophthalmology, further deepen the national "hierarchical chain" system, and enhance the scale effect
.
Build digital intelligence infrastructure projects
On January 10, He's Ophthalmology issued an announcement that in order to meet the company's business development needs, artificial intelligence, cloud computing, and big data will empower the company's intelligent upgrade, further improve operation and management efficiency, reduce project operating costs, and enhance the company's comprehensive competitiveness
.
The company intends to use the over-raised funds of 65.
3092 million yuan for the construction of the company's digital intelligence infrastructure project (phase I).
={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"share:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body).
appendChild(createElement('script')).
src='http://bdimg.
share.
baidu.
com/static/api/js/share.
js?v=89860593.
js?cdnversion='+~(-new Date()/36e5)]; 
